Jeremy Grantham's NVO Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 76.6K shares of Novo Nordisk A/S (NVO) worth $4.25 M, representing 0.01% of the portfolio. First purchased in 2016-Q1, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Jeremy Grantham has maintained a strategic position in NVO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2018, adding 1.2M shares. Largest reduction occurred in Q1 2025, reducing 1.4M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2016 | +245,200 | New Buy | 245,200 | $27.10 |
| Q2 2016 | -70,000 | Reduce 28.55% | 175,200 | $26.89 |
| Q3 2016 | -51,800 | Reduce 29.57% | 123,400 | $20.79 |
| Q4 2016 | -123,400 | Sold Out | 123,400 | $0.00 |
| Q1 2018 | +1.31 M | New Buy | 1.31 M | $24.62 |
| Q2 2018 | +49,054 | Add 3.73% | 1.36 M | $23.06 |
| Q3 2018 | +604,706 | Add 44.36% | 1.97 M | $23.57 |
| Q4 2018 | +34,200 | Add 1.74% | 2 M | $23.03 |
| Q1 2019 | +351,600 | Add 17.56% | 2.35 M | $26.15 |
| Q2 2019 | -887,200 | Reduce 37.70% | 1.47 M | $25.52 |
| Q3 2019 | -1.47 M | Sold Out | 1.47 M | $0.00 |
| Q1 2025 | +37,617 | New Buy | 37,617 | $69.44 |
| Q2 2025 | +23,968 | Add 63.72% | 61,585 | $69.02 |
| Q3 2025 | +15,027 | Add 24.40% | 76,612 | $55.49 |
Jeremy Grantham's Novo Nordisk A/S Investment FAQs
Jeremy Grantham first purchased Novo Nordisk A/S (NVO) in Q1 2016, acquiring 245,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Novo Nordisk A/S (NVO) for 39 quarters since Q1 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to Novo Nordisk A/S (NVO) was in Q1 2018, adding 1,314,000 shares worth $32.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 76,612 shares of Novo Nordisk A/S (NVO), valued at approximately $4.25 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.01% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in Novo Nordisk A/S (NVO) was 2,353,560 shares, as reported at the end of Q1 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.